This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy. Read more
News releases
Date
Language
Type of release
Company AnnouncementDownload
Full announcement
Novo Nordisk A/S: Novo Nordisk discontinues development of vatreptacog alfa following analysis of phase 3 results
Novo Nordisk today announced the decision to discontinue the development of vatreptacog alfa, a fast-acting recombinant factor VIIa analogue for haemophilia patients with inhibitors. The decision follows analysis of the data from the phase 3a trial adeptTM 2. On 9 August, Novo Nordisk announced that a few patients in the trial had developed anti-drug antibodies to vatreptacog alfa, one patient with a potentially neutralising effect.
Media: | Investors: |
| Mike Rulis | Kasper Roseeuw Poulsen |
| Tel: (+45) 3079 3573 | Tel: (+45) 4442 4303 |
| mike@novonordisk.com | krop@novonordisk.com |
| Frank Daniel Mersebach | |
| Tel: (+45) 4442 0604 | |
| fdni@novonordisk.com | |
| Lars Borup Jacobsen | |
| Tel: (+45) 3075 3479 | |
| lbpj@novonordisk.com | |
| In North America: | |
| Ken Inchausti | Jannick Lindegaard |
| Tel: (+1) 609 514 8316 | Tel: (+1) 609 786 4575 |
| kiau@novonordisk.com | jlis@novonordisk.com |
Company Announcement No 60 / 2012
